MARKET

ZBIO

ZBIO

Zenas BioPharma Inc.
NASDAQ
38.11
+1.44
+3.93%
After Hours: 38.70 +0.59 +1.55% 19:45 12/04 EST
OPEN
36.62
PREV CLOSE
36.67
HIGH
38.12
LOW
34.72
VOLUME
240.11K
TURNOVER
--
52 WEEK HIGH
41.00
52 WEEK LOW
5.83
MARKET CAP
2.05B
P/E (TTM)
-3.0084
1D
5D
1M
3M
1Y
5Y
1D
Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile?
Simply Wall St · 13h ago
Weekly Report: what happened at ZBIO last week (1124-1128)?
Weekly Report · 4d ago
Zenas BioPharma, Inc. (ZBIO) Initiated with a Buy at Evercore ISI
TipRanks · 11/27 08:15
Zenas BioPharma Initiated at Outperform by Evercore ISI Group
Dow Jones · 11/26 13:25
Zenas BioPharma Price Target Announced at $55.00/Share by Evercore ISI Group
Dow Jones · 11/26 13:25
Evercore ISI Group Initiates Coverage On Zenas BioPharma with Outperform Rating, Announces Price Target of $55
Benzinga · 11/26 13:14
Can Zenas BioPharma's (ZBIO) Improving Loss Per Share Shift Investor Confidence in Its Long-Term Story?
Simply Wall St · 11/26 07:23
Weekly Report: what happened at ZBIO last week (1117-1121)?
Weekly Report · 11/24 10:32
More
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

Webull offers Zenas BioPharma Inc. stock information, including NASDAQ: ZBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZBIO stock methods without spending real money on the virtual paper trading platform.